Domain Therapeutics Bags €39M to Block GPCRs in Cancer Immunotherapy
Domain Therapeutics, a biopharmaceutical company in France and Canada developing cancer immunotherapies targeting G protein-coupled…
As one of the leading causes of death worldwide, cancer receives great focus from the life sciences industry. Indeed, it’s the largest therapeutic focus area for biotech and pharma companies, which are working on a large number of therapeutic approaches, including small molecules, T cell therapies, and antibody therapies.
Global cancer drug sales are estimated to reach €221B by 2024. The top 10 blockbuster drugs are sold by big pharma companies, like Roche, Merck, AbbVie, and Bristol-Myers Squibb. Examples of blockbusters include Keytruda, Rituxan, and Herceptin.
Biotech companies are doing a fair bit of the work as well. Read on to keep up to date with the latest oncology research, discoveries, and market developments.
A Guide to Current Therapies in Immuno-Oncology
From a rich history to a growing number of therapies, the immuno-oncology landscape has changed rapidly over the last decade. In this report, we look into its past, discuss present therapeutic approaches, and provide an outlook into its future.
Go to ReportDomain Therapeutics, a biopharmaceutical company in France and Canada developing cancer immunotherapies targeting G protein-coupled…
In just a few years, exosomes have started gaining recognition as a solution to deliver…
As big pharma companies flock to drugs that destroy harmful proteins, the UK protein degradation…
The German firm Tubulis has raised a €60M Series B round to advance cancer drugs…
In a show of strength after an income squeeze during the Covid-19 pandemic, the charity…
The EU has followed the FDA in granting market approval to Kimmtrak, the first-ever bispecific…
Low-cost genetic sequencing is becoming increasingly accessible and profitable for companies, but data protection and…
Big European venture capital firms Jeito, Forbion, and Inkef Capital have teamed up to propel…
Chimeric antigen receptor (CAR) cell therapy offers hope where other cancer therapies have failed. However,…
Circulating tumor cell counts are powerful prognostic factors for cancer patients. Recent research has found…
The immuno-oncology startup Cytovation has raised €17.7M (NOK 180M) in one of Norway's biggest Series…
The advent of next-generation sequencing has led to the rise of novel gene expression profiling…